Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Na ïve Crohn’s Disease

ConclusionsOur real-life experience in biologic-na ïve CD patients demonstrated that patients started on IFX were more likely to have a harder-to-treat phenotype. Despite that, efficacy end points were similar between both groups. Clinical remission was higher in patients with combination therapy for IFX, but not for those on ADA. This warrants fur ther investigation.
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research